RLMD (Relmada Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is Relmada Therapeutics Days Payable?

Relmada Therapeutics RLMD +3.72% 29 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, Relmada Therapeutics ranks worse than 141642.92% on this metric.

Relmada Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $3.65 Mil. Relmada Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Relmada Therapeutics's Days Payable or its related term are showing as below:

RLMD's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Relmada Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Relmada Therapeutics Days Payable Related Terms

Relmada Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Relmada Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Days Payable Chart

Relmada Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Relmada Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

RLMD vs ALLO, PHAT, AURA: Days Payable Comparison

For the Biotechnology subindustry, Relmada Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Days Payable falls into.

Save Embed

29GF Score

Relmada Therapeutics Inc RLMD

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Relmada Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Relmada Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (4.131	+	1.569)	/	2 )	/	0	*	365
=	2.85					/	0	*	365
=	N/A

Relmada Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (1.569	+	5.731)	/	2 )	/	0	*	365 / 4
=	3.65					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Relmada Therapeutics (RLMD) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Relmada Therapeutics and its competitors. According to the industry distribution chart, Relmada Therapeutics ranks #999999 out of 706 companies in the Biotechnology industry.

Is Relmada Therapeutics' Days Payable too high?

Relmada Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Relmada Therapeutics ranks #999999 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does Relmada Therapeutics' Days Payable compare to ALLO and PHAT?

According to the Biotechnology industry distribution chart, Relmada Therapeutics ranks #999999 out of 706 companies for Days Payable. This places Relmada Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Relmada Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relmada Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Relmada Therapeutics stock overvalued right now?

Relmada Therapeutics (RLMD) has a current Days Payable of 0.00. The current Days Payable is 0.00. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ALLO PHAT AURA SMNR CTMX SLDB REPL BBOT OMER MRVI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 4E2:Germany

Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

29GF Score

Get the complete analysis for RLMD

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.67

Price

View RLMD Analysis

See Days Payable data for all stocks →